Australia markets closed

Twist Bioscience Corporation (TWST)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
42.66-0.62 (-1.43%)
As of 09:43AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.54B
Enterprise value 2.33B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)8.46
Price/book (mrq)5.16
Enterprise value/revenue 7.90
Enterprise value/EBITDA -35.26

Trading information

Stock price history

Beta (5Y monthly) 1.76
52-week change 3130.58%
S&P500 52-week change 334.08%
52-week high 360.90
52-week low 314.42
50-day moving average 345.78
200-day moving average 341.35

Share statistics

Avg vol (3-month) 3880.01k
Avg vol (10-day) 3675.42k
Shares outstanding 558.59M
Implied shares outstanding 658.59M
Float 857.7M
% held by insiders 11.72%
% held by institutions 1109.17%
Shares short (13 Sept 2024) 48.94M
Short ratio (13 Sept 2024) 411.54
Short % of float (13 Sept 2024) 419.93%
Short % of shares outstanding (13 Sept 2024) 415.26%
Shares short (prior month 15 Aug 2024) 49.21M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Sept 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin -74.63%
Operating margin (ttm)-54.00%

Management effectiveness

Return on assets (ttm)-16.39%
Return on equity (ttm)-38.36%

Income statement

Revenue (ttm)295.21M
Revenue per share (ttm)5.12
Quarterly revenue growth (yoy)27.80%
Gross profit (ttm)N/A
EBITDA -156.67M
Net income avi to common (ttm)-220.31M
Diluted EPS (ttm)-3.82
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)289.42M
Total cash per share (mrq)4.94
Total debt (mrq)87.18M
Total debt/equity (mrq)17.75%
Current ratio (mrq)4.91
Book value per share (mrq)8.39

Cash flow statement

Operating cash flow (ttm)-69.48M
Levered free cash flow (ttm)-25.09M